Equities analysts expect argenx SE – (NASDAQ:ARGX) to report earnings per share of ($0.73) for the current quarter, Zacks reports. Three analysts have provided estimates for argenx’s earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($1.01). The company is scheduled to issue its next quarterly earnings report on Thursday, October 25th.

On average, analysts expect that argenx will report full-year earnings of ($1.95) per share for the current financial year, with EPS estimates ranging from ($2.25) to ($1.64). For the next year, analysts forecast that the firm will post earnings of ($3.38) per share, with EPS estimates ranging from ($5.68) to ($2.03). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for argenx.

A number of analysts have recently commented on the stock. Wedbush lifted their price target on shares of argenx from $114.00 to $121.00 and gave the stock a “positive” rating in a research note on Tuesday, September 18th. Evercore ISI began coverage on shares of argenx in a report on Monday, October 15th. They issued an “outperform” rating and a $110.00 price objective on the stock. Piper Jaffray Companies reissued an “overweight” rating and issued a $154.00 price objective on shares of argenx in a report on Monday, September 17th. SunTrust Banks raised their price objective on shares of argenx to $132.00 and gave the stock an “in-line” rating in a report on Tuesday, September 18th. Finally, JMP Securities raised their price objective on shares of argenx to $150.00 and gave the stock an “outperform” rating in a report on Monday, September 17th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $136.00.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Redmile Group LLC boosted its holdings in shares of argenx by 44.7% in the third quarter. Redmile Group LLC now owns 974,506 shares of the company’s stock worth $73,907,000 after buying an additional 301,206 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of argenx by 1,140.2% in the third quarter. Jane Street Group LLC now owns 95,298 shares of the company’s stock worth $7,227,000 after buying an additional 87,614 shares during the last quarter. Perceptive Advisors LLC boosted its holdings in shares of argenx by 5.9% in the third quarter. Perceptive Advisors LLC now owns 560,941 shares of the company’s stock worth $42,541,000 after buying an additional 31,381 shares during the last quarter. Baker BROS. Advisors LP boosted its holdings in shares of argenx by 6.0% in the third quarter. Baker BROS. Advisors LP now owns 1,019,557 shares of the company’s stock worth $77,323,000 after buying an additional 57,803 shares during the last quarter. Finally, Bamco Inc. NY boosted its holdings in shares of argenx by 9.6% in the third quarter. Bamco Inc. NY now owns 196,740 shares of the company’s stock worth $14,921,000 after buying an additional 17,312 shares during the last quarter. 64.40% of the stock is currently owned by institutional investors.

Shares of ARGX stock opened at $105.71 on Thursday. argenx has a 52 week low of $28.83 and a 52 week high of $111.43. The company has a market capitalization of $3.11 billion, a PE ratio of -75.51 and a beta of 1.67.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Recommended Story: What are no-load funds?

Get a free copy of the Zacks research report on argenx (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.